EXPEDITED REVIEW
The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS)
Erick Schampaert, MD*,*,
Eric A. Cohen, MD ,
Michael Schlüter, PhD ,
François Reeves, MD ,
Mouhieddin Traboulsi, MD||,
Lawrence M. Title, MD¶,
Richard E. Kuntz, MD, MSc, FACC#,
Jeffrey J. Popma, MD, FACC# the C-SIRIUS Investigators
* Hôpital du Sacré-Coeur de Montréal, Montreal, Canada
Sunnybrook and Women's College Health Sciences Centre, Toronto, Canada
Center for Cardiology and Vascular Intervention, Hamburg, Germany
Centre Hospitalier de l'Université de Montréal, Pavillon Notre-Dame, Montreal, Canada
|| Calgary Heart Centre, Calgary, Canada
¶ Queen Elizabeth II Health Science Centre, Halifax, Nova Scotia, Canada
# Brigham and Women's Hospital, Boston, Massachusetts, USA
Manuscript received November 6, 2003;
revised manuscript received January 6, 2004,
accepted January 12, 2004.
* Reprint requests and correspondence: Dr. Erick Schampaert, Hôpital du Sacré-Coeur de Montréal, 5400 Bl. Gouin O., Montréal, Québec, Canada H4J 1C5.
erick.schampaert.hsc{at}ssss.gouv.qc.ca
 |
Abstract
|
|---|
OBJECTIVES: We assessed the safety and effectiveness of the sirolimus-eluting stent (SES) in treating single de novo long lesions in small native coronary arteries compared to an identical bare metal stent (BMS).
BACKGROUND: The SES was previously demonstrated to reduce restenosis significantly. However, patients with long lesions in small vessels have not been well studied and may define a group at very high risk.
METHODS: The Canadian Study of the Sirolimus-Eluting Stent in the Treatment of Patients With Long De Novo Lesions in Small Native Coronary Arteries (C-SIRIUS) was a multicenter, randomized, double-blind trial comparing SES versus identical BMS. The primary end point was in-stent minimal lumen diameter (MLD) at eight months. Secondary end points included angiographic restenosis at 8 months, target lesion revascularization (TLR), and major adverse cardiac events (MACE) at 270 days.
RESULTS: A total of 100 patients were enrolled at eight Canadian sites. The in-stent MLD at eight months was 2.46 ± 0.37 mm in the SES compared with 1.49 ± 0.75 mm in the BMS (a 65% increase, p < 0.001). Angiographic restenosis occurred in 1 of 44 SES patients (2.3%, with no in-stent restenosis) and in 23 of 44 BMS patients (52.3%, p < 0.001). At 270 days, there were two clinically driven TLRs in the SES (4%) and nine in the BMS (18%, p = 0.05). The Kaplan-Meier estimate of freedom from MACE at 270 days was 96.0% for SES patients and 81.7% for BMS patients (p = 0.029).
CONCLUSIONS: Patients with long lesions in small vessels are at very high risk of restenosis. In these patients, the SES dramatically reduces the risk of restenosis at eight months, translating into an excellent clinical outcome at nine months.
|
Abbreviations and Acronyms
| | BMS | = bare metal stent | | ISR | = in-stent restenosis | | MACE | = major adverse cardiac events | | MLD | = minimal lumen diameter | | PCI | = percutaneous coronary intervention | | QCA | = quantitative coronary angiography | | SES | = sirolimus-eluting stent | | TLR | = target lesion revascularization |
|
Stent implantation has become the standard percutaneous coronary intervention (PCI) (1–3). However, in-stent restenosis (ISR) within three to eights months has continued to limit the long-term success of this therapy (4). Neointimal hyperplasia has been identified as the main mechanism of ISR (5,6). Predictors of ISR include a reference vessel diameter smaller than 3.0 mm, lesion lengths above 10 mm, and diabetes mellitus (7–9). Although intracoronary brachytherapy is available to treat established ISR (10), stents eluting pharmaceutical agents capable of suppressing neointimal hyperplasia represent a promising approach to prevent ISR (11).
Preclinical experiments of such an agent, sirolimus (rapamycin), suggested efficacy and safety (12,13). A powerful natural immunosuppressive macrocyclic lactone, it inhibits cytokine-mediated proliferation and migration of lymphocytes and smooth muscle cells (14). Incorporated into a biocompatible non-erodable stent polymer, sirolimus is released into the stented vessel segment over a period of 90 days.
Four clinical trials with the sirolimus-eluting stent (SES) have enrolled patients with de novo lesions in native coronary arteries, with a pattern of increasing lesion complexity (determined by vessel size and lesion length) in successive trials. The "First-in-Man" study (15) restricted treatment to the implantation of a single 18-mm stent in vessels 3.0 to 3.5 mm in diameter, guided by intravascular ultrasound. The subsequent Randomized Study with the Sirolimus-Coated Bx-VELOCITY Balloon-Expandable Stent in the Treatment of Patients with De Novo Native Coronary Artery Lesions (RAVEL) (16) included vessels 2.5 to 3.5 mm in diameter, but still to be covered with a single stent. The pivotal Sirolimus-Eluting Stent in De Novo Native Coronary Lesions (SIRIUS) trial (17) enrolled patients with longer lesions of 15 to 30 mm, again in 2.5 to 3.5 mm vessels. Finally, in E-SIRIUS (18), patients with a target lesion length of 15 to 32 mm in smaller vessels 2.5 to 3.0 mm in diameter, were randomized to the SES versus a bare metal stent (BMS) of identical architecture.
During the same period, in Canada we conducted a randomized, multicenter trial based on the same protocol as E-SIRIUS, targeting the same patients with long lesions, potentially requiring multiple stents, in small coronary arteries—all conditions that are known to increase the risk of restenosis. Contemporary interventional techniques, including direct stenting, were allowed.
|
Patients and methods
|
|---|
Patients.
This study was a randomized, double-blind trial involving eight Canadian teaching hospitals (Appendix). Patients were at least 18 years old, with documented angina pectoris (Canadian Cardiovascular Society angina class 1 to 4), unstable angina (Braunwald classification B and C, I or II), or silent ischemia. Their PCI target had to be a single de novo lesion in a native vessel, between 15 and 32 mm in length, and with a diameter stenosis of 50% to 99%. The vessel diameter was limited to 2.5 to 3.0 mm. All angiographic criteria were based on visual assessment. Major exclusion criteria were the same as E-SIRIUS (18). The study protocol was approved by the ethics committee at each participating center, and all patients gave written informed consent.
Study stents.
The control stents used were the bare metal Bx-VELOCITY stent (J&J Cordis, Miami Lakes, Florida), which is a balloon-expandable, tubular 316L stainless-steel stent pre-mounted on a monorail balloon-dilation catheter. The study stents, using the same Bx-VELOCITY platform, had a 5-µm coating consisting of a blend of 33% sirolimus and 67% of a non-erodable polymer. The drug-polymer matrix contains 140 µg of sirolimus per cm2 of surface area. A drug-free polymer topcoat serves as a control drug release barrier, such that 80% of sirolimus is released within 30 days of implantation and with no residual drug by 90 days. The SES (brand name, Cypher) is visually and radiographically indistinguishable from its uncoated counterpart, allowing for the double-blind design of the trial.
Study procedures.
As previously described (18), patients were randomly assigned either to sirolimus or control stents by means of sealed randomization envelopes. Neither the operator nor the patient knew which stent would be implanted.
According to standard care, patients were pre-medicated with 81 to 325 mg of aspirin, begun at least 12 h before the procedure, and clopidogrel, administered as a loading dose of 300 mg before or immediately after the procedure. During the procedure, intravenous boluses of heparin were administered to maintain an activated clotting time in excess of 250 s. The use of glycoprotein IIb/IIIa receptor antagonists was left to the investigator's discretion.
Stent implantation followed current accepted techniques, as described (18). One distinguishing feature of this study, compared with previous trials, was to allow "direct stenting" (without lesion pre-dilation) in centers where this was standard practice. The decision to pre-dilate or not was left to the investigator. Heparin was discontinued immediately after the procedure. Patients were discharged on a regimen of aspirin (81 to 325 mg/day indefinitely) and clopidogrel (75 mg/day) for two months only.
Follow-up.
Patients were evaluated clinically at 30, 90, 180, and 270 days. A repeat angiographic study was scheduled after eight months in all patients.
Definitions.
At the outset we distinguished between "in-stent" and "in-lesion" angiographic variables, with the former referring to the vessel segment inside the stent and the latter including the 5-mm vessel segments adjacent to the proximal and distal stent edges. Late luminal loss was defined as the difference between the minimal lumen diameter (MLD) at eight months and the MLD post-procedure.
Study end points.
The primary end point of this study was in-stent MLD at eight months, determined by quantitative coronary angiography (QCA). Secondary end points included: eight-month angiographic in-lesion MLD; in-stent and in-lesion angiographic restenosis (a  50% diameter stenosis by QCA); major adverse cardiac events (MACE)—a composite end point comprising death, myocardial infarction, emergent coronary artery bypass surgery, and clinically driven repeat target lesion revascularization (TLR)—all at nine months; and TLR at nine months. A clinically driven TLR procedure was defined as one done in response to recurrent angina and/or documented ischemia on noninvasive tests (all recorded prior to repeat angiography), with >50% diameter stenosis by QCA, or >70% diameter stenosis by QCA in the absence of symptoms.
Offline QCA at baseline, post-procedure, and after eight months was performed by an independent core laboratory (Brigham and Women's Hospital Angiographic Core Laboratory, Boston, Massachusetts). All clinical end points were adjudicated by an independent clinical events committee.
Data management and statistical methods.
At each participating center, patients' data were prospectively recorded on standard case report forms. Complete data monitoring was performed by an independent clinical research consulting firm (DT Consultant, Montreal, Canada), which forwarded the completed case report forms to the study coordinating center for data entry and analysis. Treatment allocation was unblinded at Harvard Clinical Research Institute after nine-month clinical follow-up for analysis. However, individual patient assignment has remained blinded for unbiased clinical follow-up to five years. All data were held at the study coordinating center, but the authors of this report had full access to them.
Based on the hypothesis that in-stent MLD by QCA at eight months would be 1.6 mm for the control stent and 2.4 mm for the SES, with a common standard deviation of 0.7 mm, detecting this difference with an 80% power and a two-sided alpha error of 5%, would require a sample size of <60 patients (30 patients per study arm). Adjusting for an 80% compliance with eight-month angiographic follow-up, the sample size of 100 patients was judged adequate. All analyses were based on the intention-to-treat principle. Continuous variables are presented as mean value ± SD, with differences between groups assessed by the Student unpaired t test. Discrete variables are presented as counts and percentages, with differences between groups assessed by the Fisher exact test. The Kaplan-Meier method was used to analyze the occurrence of the composite end point of MACE during the nine-month period of follow-up, with differences between event-free survival curves assessed by log-rank test. Statistical significance was assumed at the 5% level (p < 0.05).
|
Results
|
|---|
Between November 2001 and April 2002, we enrolled 102 patients. Two patients were randomized (one in each group) but subsequently deregistered because no study stent implantation was attempted (one patient underwent coronary artery bypass grafting after failure to cross the lesion with a guidewire and one patient was withdrawn from the study after failed predilation with standard balloons). Thus, 100 patients entered the trial for end point analysis, with 50 patients receiving an SES and 50 patients receiving uncoated control BMS. Baseline characteristics of the patients (Table 1) were well matched between groups, with 24% of patients having diabetes mellitus.
Device success, defined as the achievement of <50% residual diameter stenosis with the assigned stent, was 100% in both groups.
The mean lesion length as measured by QCA was 13.6 ± 5.8 mm, in vessels with a mean reference diameter of 2.63 ± 0.33 mm. Glycoprotein IIb/IIIa inhibitors were administered to 53% of patients. The average number of stents implanted was 1.5 ± 0.7 per patient, with two or more stents implanted in 40% of patients. This resulted in a mean total stent length of 23.8 ± 8.4 mm and a stent length to lesion length ratio of 1.8 ± 0.8. Direct stenting was performed in 31% of cases. Of the stented lesions, 64% were post-dilated (using a shorter balloon in one-half the cases), with a mean maximum pressure of 17.3 ± 3.4 atm and a nominal balloon to artery ratio of 1.0 ± 0.1.
Immediate post-procedure results were similar for SES and BMS, with a mean in-stent MLD of 2.51 ± 0.29 mm, and residual in-stent and in-lesion stenoses of 5.7% and 17.9%, respectively.
Eight-month angiographic follow-up was available in 88% of patients, with 44 patients in each group. The eight-month in-stent MLD, the primary end point, was significantly greater in the SES group at 2.46 ± 0.37 mm vs. the BMS group at 1.49 ± 0.75 mm (a 65% increase, p < 0.001) (Table 2). The corresponding late luminal loss was reduced by 90%, from 1.02 ± 0.69 mm to 0.12 ± 0.37 mm (p < 0.001) (Table 2). The eight-month in-lesion MLD was also significantly improved in the SES group compared to the BMS group (Table 2). Consequently, the in-lesion late luminal loss was significantly reduced in the SES patients (Table 2), with an effect demonstrated both at the proximal and distal stent edges (Fig, 1). Angiographic restenosis occurred in 1 of 44 SES patients (2.3%), with no ISR, and in 23 of 44 BMS patients (52.3%, p < 0.001). The single SES patient with in-lesion restenosis had a 58% stenosis proximal to the SES stent. The relative reductions in eight-month binary restenosis associated with use of the SES were thus 96% within the lesion and 100% within the stent. No aneurysms were seen.
View larger version (12K):
[in this window]
[in a new window]
|
Figure 1 Late luminal loss by quantitative coronary angiography. Proximal edge: the 5-mm proximal to the stent. Distal edge: the 5-mm distal to the stent. Late loss was defined as the difference between the in-stent minimal lumen diameter at follow-up and the post-procedure in-stent minimal lumen diameter.
|
|
Major adverse cardiac events at 270 days for all 100 patients are listed in Table 3. There were no deaths and no Q-wave myocardial infarctions. Stent thrombosis occurred in one patient in each group (on day 8 in an SES patient after an initially successful intervention involving three stents in a small right coronary artery, and on day 57 in a BMS patient), requiring TLR in both cases. Eight additional clinically driven TLR procedures occurred in the BMS group and one such procedure in the SES group, for a total TLR rate at nine months of 18% and only 4%, respectively (p = 0.05). Only two BMS patients sustained a non-clinically driven TLR following repeat angiography at eight months. Consequently, the Kaplan-Meier estimate of freedom from MACE at 270 days was 96.0% for SES patients and 81.7% for BMS patients (p = 0.029) (Fig. 2).
View larger version (13K):
[in this window]
[in a new window]
|
Figure 2 Survival free from major adverse cardiac events (MACE). Absolute risk reduction: 14.3%, p = 0.029.
|
|
|
Discussion
|
|---|
Compared with previous trials (15–17), the patients enrolled in this Canadian multicenter controlled trial, along with the E-SIRIUS patients (18), had a higher clinical-risk profile for restenosis: long target lesions, small target vessels, multiple stents in 40% of cases, and a mean implanted stent length of 23.8 mm. This is reflected in the progressive increase of the in-lesion restenosis rate of the BMS group: 26.6% in RAVEL (16), 36.3% in SIRIUS (17), 42.3% in E-SIRIUS, and 52.3% in our trial. Despite the higher risk profile of our patients, the eight-month in-stent and in-lesion MLDs were well maintained in the SES patients. Late luminal loss at the proximal and distal edges of the SES was reduced by 77% and 100%, respectively, compared with the BMS, suggesting a true protective effect of the SES at the stent margins. Consequently, the angiographic restenosis rate following SES implantation was only 2.3%, with no ISR. These findings confirm the efficacy of the SES to prevent restenosis, as observed in all previous trials (15–18). Thus, the need for a clinically driven revascularization procedure, prompted by recurrent angina and/or documented ischemia, fell from 18% in BMS patients to 4% in SES patients. This means that for every 1,000 patients undergoing stent implantation for a native coronary artery lesion of the type included in this study, 140 patients may be spared from clinical restenosis and repeat intervention at nine months by initial treatment with SES.
Because the same SES was used in four randomized trials, certain observations regarding the SES patients across the trials may be relevant. The somewhat higher in-lesion restenosis rate observed in SIRIUS (8.9%), compared with RAVEL (0%), E-SIRIUS (5.9%), and C-SIRIUS (2.3%), was associated with more proximal margin restenosis: 5.8% in SIRIUS (especially in patients with the smallest vessels), compared with 0%, 2.1%, and 2.3% in RAVEL, E-SIRIUS, and C-SIRIUS, respectively. This difference could be related to subtle but more frequent or pronounced proximal edge trauma during pre-dilation, stent implantation, or post-deployment dilation, overwhelming the protective effect at the SES proximal margin. The use of direct stenting in E-SIRIUS and C-SIRIUS may also have limited proximal edge trauma and subsequent restenosis in some patients. Taken together with the observation that the total stent length to lesion length ratio of 1.8 in our trial was identical to that in RAVEL and E-SIRIUS suggests that meticulous (and generous) coverage of all the injured and diseased vessel area appears to be desirable.
|
Conclusions
|
|---|
The C-SIRIUS demonstrated that patients with long lesions in small vessels are at very high risk of restenosis. In these patients, the SES dramatically reduced the risk of restenosis, with no ISR at eight months, translating into an excellent clinical outcome at nine months. Ongoing follow-up will evaluate the durability of these clinical benefits over the next four years.
|
APPENDIX
|
|---|
Investigators in the Canadian Study of the Sirolimus-Eluting Stent in the Treatment of Patients With Long De Novo Lesions in Small Native Coronary Arteries (C-SIRIUS): E. A. Cohen (Sunnybrook and Women's College Health Sciences Centre, Toronto), F. Reeves (Centre Hospitalier de l'Université de Montréal, Pavillon Notre-Dame), E. Schampaert (Hôpital du Sacré-Coeur de Montréal), D. Traboulsi (Calgary Heart Centre) L. Title (Queen Elizabeth II Health Science Centre, Halifax), D. Raco (Hamilton General Hospital), S. Plante (Hôpital Laval, Québec), and R. Mildenberger (Victoria Heart Centre). Study coordination: R. E. Kuntz (Harvard Clinical Research Institute [HCRI], Boston, Massachusetts).
For a complete list of the investigators and hospitals participating in C-SIRIUS, please see the March 17, 2004, issue of JACC at http://www.cardiosource.com/jacc.html .
|
Footnotes
|
|---|
This study was sponsored by Cordis Canada, a Johnson & Johnson Company, the manufacturer of the study stents.
|
References
|
|---|
1. Fischman DL, Leon MB, Baim DS, et al. for the Stent Restenosis Study Investigators. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496–501
2. Serruys PW, de Jaegere P, Kiemeneij F, et al. for the Benestent Study Group. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489–495
3. Al Suwaidi J, Berger PB, Holmes DR Jr. Coronary artery stents. JAMA. 2000;284:1828–1836[Abstract/Free Full Text]
4. Kastrati A, Schömig A, Dietz R, Neumann FJ, Richardt G. Time course of restenosis during the first year after emergency coronary stenting. Circulation. 1993;87:1498–1505[Abstract/Free Full Text]
5. Gordon PC, Gibson CM, Cohen DJ, Carrozza JP, Kuntz RE, Baim DS. Mechanism of restenosis and redilatation within coronary stents: quantitative angiographic assessment. J Am Coll Cardiol. 1993;21:1166–1174[Abstract]
6. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998;31:224–230[Abstract/Free Full Text]
7. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 1996;94:1247–1254[Abstract/Free Full Text]
8. Kastrati A, Schömig A, Elezi S, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol. 1997;30:1428–1436[Abstract]
9. Bauters C, Hubert E, Prat A, et al. Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol. 1998;31:1291–1298[Abstract/Free Full Text]
10. Leon MB, Teirstein PS, Moses JW, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med. 2001;344:250–256[Abstract/Free Full Text]
11. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: part II. Circulation. 2003;107:2383–2389[Free Full Text]
12. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 1999;99:2164–2170[Abstract/Free Full Text]
13. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001;104:1188–1193[Abstract/Free Full Text]
14. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation. 2001;104:852–855[Free Full Text]
15. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001;104:2007–2011[Abstract/Free Full Text]
16. Morice MC, Serruys PW, Sousa JE, et al. for the RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–1780
17. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323[Abstract/Free Full Text]
18. Schofer J, Schlüter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS). Lancet. 2003;362:1093–1099[CrossRef][Medline]
This article has been cited by other articles:
|
|
|
|
 
T. Higo, Y. Ueda, J. Oyabu, K. Okada, M. Nishio, A. Hirata, K. Kashiwase, N. Ogasawara, S. Hirotani, and K. Kodama
Atherosclerotic and thrombogenic neointima formed over sirolimus drug-eluting stent an angioscopic study.
J. Am. Coll. Cardiol. Img.,
May 1, 2009;
2(5):
616 - 624.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ishii, Y. Kumada, T. Toriyama, T. Aoyama, H. Takahashi, T. Amano, Y. Yasuda, Y. Yuzawa, S. Maruyama, S. Matsuo, et al.
Aortic valvular calcification predicts restenosis after implantation of drug-eluting stents in patients on chronic haemodialysis
Nephrol. Dial. Transplant.,
May 1, 2009;
24(5):
1562 - 1567.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Han, Q. Jing, B. Xu, L. Yang, H. Liu, X. Shang, T. Jiang, Z. Li, H. Zhang, H. Li, et al.
Safety and Efficacy of Biodegradable Polymer-Coated Sirolimus-Eluting Stents in "Real-World" Practice: 18-Month Clinical and 9-Month Angiographic Outcomes
J. Am. Coll. Cardiol. Intv.,
April 1, 2009;
2(4):
303 - 309.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Philpott MD, D. A. Southern MSc, F. M. Clement PhD, P. D. Galbraith BN MSc, M. Traboulsi MD, M. L. Knudtson MD, W. A. Ghali MD, and for the APPROACH Investigators
Long-term outcomes of patients receiving drug-eluting stents
Can. Med. Assoc. J.,
January 20, 2009;
180(2):
167 - 174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/writing members:, J. Daemen, M. L. Simoons, W. Wijns, A. Bagust, G. Bos, J. M. Bowen, E. Braunwald, E. Camenzind, B. Chevalier, et al.
Meeting Report: ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007
Eur. Heart J.,
January 2, 2009;
30(2):
152 - 161.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Austin, K. G. Oldroyd, A. McConnachie, R. Slack, H. Eteiba, A. D. Flapan, K. P. Jennings, R. J. Northcote, A. C.H. Pell, I. R. Starkey, et al.
Drug-Eluting Stents Versus Bare-Metal Stents for Off-Label Indications: A Propensity Score-Matched Outcome Study
Circ Cardiovasc Intervent,
August 1, 2008;
1(1):
45 - 52.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. R. Brodie, T. Stuckey, W. Downey, A. Humphrey, B. Bradshaw, C. Metzger, J. Hermiller, F. Krainin, S. Juk, B. Cheek, et al.
Outcomes and Complications With Off-Label Use of Drug-Eluting Stents: Results From the STENT (Strategic Transcatheter Evaluation of New Therapies) Group
J. Am. Coll. Cardiol. Intv.,
August 1, 2008;
1(4):
405 - 414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. T. Newsome, M. A. Kutcher, and R. L. Royster
Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention
Anesth. Analg.,
August 1, 2008;
107(2):
552 - 569.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Mahmud, G. Bromberg-Marin, V. Palakodeti, L. Ang, D. Creanga, and A. N. DeMaria
Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis.
J. Am. Coll. Cardiol.,
June 24, 2008;
51(25):
2385 - 2395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G Raja and G. D Dreyfus
Current Status of Off-pump Coronary Artery Bypass Surgery
Asian Cardiovasc Thorac Ann,
April 1, 2008;
16(2):
164 - 178.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Kip, K. Hollabaugh, O. C. Marroquin, and D. O. Williams
The Problem With Composite End Points in Cardiovascular Studies The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention.
J. Am. Coll. Cardiol.,
February 19, 2008;
51(7):
701 - 707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Jeremias and A. Kirtane
Balancing Efficacy and Safety of Drug-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention
Ann Intern Med,
February 5, 2008;
148(3):
234 - 238.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. G. Nuhrenberg, N. Langwieser, J. B.K. Schwarz, Y. Hou, P. Frank, F. Sorge, S. Matschurat, S. Seidl, A. Kastrati, A. Schomig, et al.
EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury
Cardiovasc Res,
February 1, 2008;
77(3):
580 - 589.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. C. Marroquin, F. Selzer, S. R. Mulukutla, D. O. Williams, H. A. Vlachos, R. L. Wilensky, J.-F. Tanguay, E. M. Holper, J. D. Abbott, J. S. Lee, et al.
A Comparison of Bare-Metal and Drug-Eluting Stents for Off-Label Indications
N. Engl. J. Med.,
January 24, 2008;
358(4):
342 - 352.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
American College of Cardiology/American Heart Asso, 2007 Writing Group to Review New Evidence and Upda, S. B. King III, S. C. Smith Jr, J. W. Hirshfeld Jr, A. K. Jacobs, D. A. Morrison, and D. O. Williams
2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention
J. Am. Coll. Cardiol.,
January 15, 2008;
51(2):
172 - 209.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B. King III, S. C. Smith Jr, J. W. Hirshfeld Jr, A. K. Jacobs, D. A. Morrison, D. O. Williams, 2005 WRITING COMMITTEE MEMBERS, S. C. Smith Jr, T. E. Feldman, J. W. Hirshfeld Jr, et al.
2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee
Circulation,
January 15, 2008;
117(2):
261 - 295.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Pocock, A. J. Lansky, R. Mehran, J. J. Popma, M. P. Fahy, Y. Na, G. Dangas, J. W. Moses, T. Pucelikova, D. E. Kandzari, et al.
Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials.
J. Am. Coll. Cardiol.,
January 1, 2008;
51(1):
23 - 32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Wilson and J. T. Willerson
Myocardial Revascularization with Percutaneous Devices
Card. Surg. Adult,
January 1, 2008;
3(2008):
573 - 598.
[Full Text]
|
|
|
|
|
|
|
E. Solinas, E. Nikolsky, A. J. Lansky, A. J. Kirtane, M.-C. Morice, J. J. Popma, J. Schofer, E. Schampaert, T. Pucelikova, J. Aoki, et al.
Gender-Specific Outcomes After Sirolimus-Eluting Stent Implantation
J. Am. Coll. Cardiol.,
November 27, 2007;
50(22):
2111 - 2116.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-C. Morice, P. W. Serruys, P. Barragan, C. Bode, G.-A. Van Es, H.-P. Stoll, D. Snead, L. Mauri, D. E. Cutlip, and E. Sousa
Long-Term Clinical Outcomes With Sirolimus-Eluting Coronary Stents: Five-Year Results of the RAVEL Trial
J. Am. Coll. Cardiol.,
October 2, 2007;
50(14):
1299 - 1304.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Simonton, B. Brodie, B. Cheek, F. Krainin, C. Metzger, J. Hermiller, S. Juk, P. Duffy, A. Humphrey, M. Nussbaum, et al.
Comparative Clinical Outcomes of Paclitaxel- and Sirolimus-Eluting Stents: Results From a Large Prospective Multicenter Registry STENT Group
J. Am. Coll. Cardiol.,
September 25, 2007;
50(13):
1214 - 1222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bode and M. Zehender
The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis
Eur. Heart J. Suppl.,
August 1, 2007;
9(suppl_D):
D10 - D19.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Vermeersch, P. Agostoni, S. Verheye, P. Van den Heuvel, C. Convens, F. Van den Branden, G. Van Langenhove, and DELAYED RRISC (Death and Events at Long-term follo
Increased Late Mortality After Sirolimus-Eluting Stents Versus Bare-Metal Stents in Diseased Saphenous Vein Grafts: Results From the Randomized DELAYED RRISC Trial
J. Am. Coll. Cardiol.,
July 17, 2007;
50(3):
261 - 267.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Daemen and P. W. Serruys
Drug-Eluting Stent Update 2007: Part I: A Survey of Current and Future Generation Drug-Eluting Stents: Meaningful Advances or More of the Same?
Circulation,
July 17, 2007;
116(3):
316 - 328.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Moreno, C. Fernandez, A. Sanchez-Recalde, G. Galeote, L. Calvo, F. Alfonso, R. Hernandez, R. Sanchez-Aquino, D. J. Angiolillo, S. Villarreal, et al.
Clinical impact of in-stent late loss after drug-eluting coronary stent implantation
Eur. Heart J.,
July 1, 2007;
28(13):
1583 - 1591.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W. Stone, S. G. Ellis, A. Colombo, K. D. Dawkins, E. Grube, D. E. Cutlip, M. Friedman, D. S. Baim, and J. Koglin
Offsetting Impact of Thrombosis and Restenosis on the Occurrence of Death and Myocardial Infarction After Paclitaxel-Eluting and Bare Metal Stent Implantation
Circulation,
June 5, 2007;
115(22):
2842 - 2847.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H Wong, S. Wan, and M. J Underwood
Myocardial Revascularization: Surgery or Stenting?
Asian Cardiovasc Thorac Ann,
June 1, 2007;
15(3):
264 - 269.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Rinfret and E. Schampaert
Drug-eluting stents
Can. Med. Assoc. J.,
May 22, 2007;
176(11):
1611 - 1612.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Beohar, C. J. Davidson, K. E. Kip, L. Goodreau, H. A. Vlachos, S. N. Meyers, K. H. Benzuly, J. D. Flaherty, M. J. Ricciardi, C. L. Bennett, et al.
Outcomes and Complications Associated With Off-Label and Untested Use of Drug-Eluting Stents
JAMA,
May 9, 2007;
297(18):
1992 - 2000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Camenzind, P. G. Steg, and W. Wijns
A Cause for Concern
Circulation,
March 20, 2007;
115(11):
1440 - 1455.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Spaulding, J. Daemen, E. Boersma, D. E. Cutlip, and P. W. Serruys
A Pooled Analysis of Data Comparing Sirolimus-Eluting Stents with Bare-Metal Stents
N. Engl. J. Med.,
March 8, 2007;
356(10):
989 - 997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W. Stone, J. W. Moses, S. G. Ellis, J. Schofer, K. D. Dawkins, M.-C. Morice, A. Colombo, E. Schampaert, E. Grube, A. J. Kirtane, et al.
Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents
N. Engl. J. Med.,
March 8, 2007;
356(10):
998 - 1008.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kastrati, J. Mehilli, J. Pache, C. Kaiser, M. Valgimigli, H. Kelbaek, M. Menichelli, M. Sabate, M. J. Suttorp, D. Baumgart, et al.
Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents
N. Engl. J. Med.,
March 8, 2007;
356(10):
1030 - 1039.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Mauri, W.-h. Hsieh, J. M. Massaro, K. K.L. Ho, R. D'Agostino, and D. E. Cutlip
Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents
N. Engl. J. Med.,
March 8, 2007;
356(10):
1020 - 1029.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-P. B.-L. Rocca, C. Kaiser, M. Pfisterer, and on behalf of the BASKET Investigators
Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET)
Eur. Heart J.,
March 2, 2007;
28(6):
719 - 725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Valgimigli, K. Dawkins, C. Macaya, B. de Bruyne, E. Teiger, J. Fajadet, R. Gert, S. De Servi, A. Ramondo, K. Wittebols, et al.
Impact of Stable Versus Unstable Coronary Artery Disease on 1-Year Outcome in Elective Patients Undergoing Multivessel Revascularization With Sirolimus-Eluting Stents: A Subanalysis of the ARTS II Trial
J. Am. Coll. Cardiol.,
January 30, 2007;
49(4):
431 - 441.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ligthart, F. Vlemmix, N. Dendukuri, and J. M. Brophy
The cost-effectiveness of drug-eluting stents: a systematic review
Can. Med. Assoc. J.,
January 16, 2007;
176(2):
199 - 205.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Kandzari, M. B. Leon, J. J. Popma, P. J. Fitzgerald, C. O'Shaughnessy, M. W. Ball, M. Turco, R. J. Applegate, P. A. Gurbel, M. G. Midei, et al.
Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients With Native Coronary Artery Disease: A Randomized Controlled Trial
J. Am. Coll. Cardiol.,
December 19, 2006;
48(12):
2440 - 2447.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Vermeersch, P. Agostoni, S. Verheye, P. Van den Heuvel, C. Convens, N. Bruining, F. Van den Branden, and G. Van Langenhove
Randomized Double-Blind Comparison of Sirolimus-Eluting Stent Versus Bare-Metal Stent Implantation in Diseased Saphenous Vein Grafts: Six-Month Angiographic, Intravascular Ultrasound, and Clinical Follow-Up of the RRISC Trial
J. Am. Coll. Cardiol.,
December 19, 2006;
48(12):
2423 - 2431.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Nordmann, M. Briel, and H. C. Bucher
Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis
Eur. Heart J.,
December 1, 2006;
27(23):
2784 - 2814.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Holmes Jr, J. W. Moses, J. Schofer, M.-C. Morice, E. Schampaert, and M. B. Leon
Cause of death with bare metal and sirolimus-eluting stents
Eur. Heart J.,
December 1, 2006;
27(23):
2815 - 2822.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. O. Williams, J. D. Abbott, K. E. Kip, and for the DEScover Investigators
Outcomes of 6906 Patients Undergoing Percutaneous Coronary Intervention in the Era of Drug-Eluting Stents: Report of the DEScover Registry
Circulation,
November 14, 2006;
114(20):
2154 - 2162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Corbett, J. Cosgrave, G. Melzi, R. Babic, G. G.L. Biondi-Zoccai, C. Godino, N. Morici, F. Airoldi, I. Michev, M. Montorfano, et al.
Patterns of restenosis after drug-eluting stent implantation: insights from a contemporary and comparative analysis of sirolimus- and paclitaxel-eluting stents
Eur. Heart J.,
October 1, 2006;
27(19):
2330 - 2337.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Futamatsu, M. Sabate, D. J. Angiolillo, P. Jimenez-Quevedo, C. Corros, K. Morikawa-Futamatsu, F. Alfonso, J. Jiang, P. Cervinka, R. Hernandez-Antolin, et al.
Characterization of Plaque Prolapse After Drug-Eluting Stent Implantation in Diabetic Patients: A Three-Dimensional Volumetric Intravascular Ultrasound Outcome Study
J. Am. Coll. Cardiol.,
September 19, 2006;
48(6):
1139 - 1145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Suttorp, G. J. Laarman, B. M. Rahel, J. C. Kelder, M. A.R. Bosschaert, F. Kiemeneij, J. M. ten Berg, E. T. Bal, B. J. Rensing, F. D. Eefting, et al.
Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): A Randomized Comparison of Bare Metal Stent Implantation With Sirolimus-Eluting Stent Implantation for the Treatment of Total Coronary Occlusions
Circulation,
August 29, 2006;
114(9):
921 - 928.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Kereiakes, H. Wang, J. J. Popma, R. E. Kuntz, D. J. Donohoe, J. Schofer, E. Schampaert, B. Meier, M. B. Leon, and J. W. Moses
Periprocedural and Late Consequences of Overlapping Cypher Sirolimus-Eluting Stents: Pooled Analysis of Five Clinical Trials
J. Am. Coll. Cardiol.,
July 4, 2006;
48(1):
21 - 31.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Joner, A. V. Finn, A. Farb, E. K. Mont, F. D. Kolodgie, E. Ladich, R. Kutys, K. Skorija, H. K. Gold, and R. Virmani
Pathology of Drug-Eluting Stents in Humans: Delayed Healing and Late Thrombotic Risk
J. Am. Coll. Cardiol.,
July 4, 2006;
48(1):
193 - 202.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Cosgrave, G. Melzi, G. G.L. Biondi-Zoccai, F. Airoldi, A. Chieffo, G. M. Sangiorgi, M. Montorfano, I. Michev, M. Carlino, E. Bonizzoni, et al.
Drug-Eluting Stent Restenosis: The Pattern Predicts the Outcome
J. Am. Coll. Cardiol.,
June 20, 2006;
47(12):
2399 - 2404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Roiron, P Sanchez, A Bouzamondo, P Lechat, and G Montalescot
Drug eluting stents: an updated meta-analysis of randomised controlled trials
Heart,
May 1, 2006;
92(5):
641 - 649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Stettler, S Allemann, M Egger, S Windecker, B Meier, and P Diem
Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials
Heart,
May 1, 2006;
92(5):
650 - 657.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Rodriguez, J. F. Granada, M. Rodriguez-Alemparte, C. F. Vigo, J. Delgado, C. Fernandez-Pereira, A. Pocovi, A. M. Rodriguez-Granillo, D. Schulz, A. E. Raizner, et al.
Oral Rapamycin After Coronary Bare-Metal Stent Implantation to Prevent Restenosis: The Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study
J. Am. Coll. Cardiol.,
April 18, 2006;
47(8):
1522 - 1529.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Weisz, M. B. Leon, D. R. Holmes Jr, D. J. Kereiakes, M. R. Clark, B. M. Cohen, S. G. Ellis, P. Coleman, C. Hill, C. Shi, et al.
Two-Year Outcomes After Sirolimus-Eluting Stent Implantation: Results From the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) Trial
J. Am. Coll. Cardiol.,
April 4, 2006;
47(7):
1350 - 1355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Urban, A. H. Gershlick, G. Guagliumi, P. Guyon, C. Lotan, J. Schofer, A. Seth, J. E. Sousa, W. Wijns, C. Berge, et al.
Safety of Coronary Sirolimus-Eluting Stents in Daily Clinical Practice: One-Year Follow-Up of the e-Cypher Registry
Circulation,
March 21, 2006;
113(11):
1434 - 1441.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Raja
Drug-Eluting Stents and the Future of Coronary Artery Bypass Surgery: Facts and Fiction.
Ann. Thorac. Surg.,
March 1, 2006;
81(3):
1162 - 1171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-C. Morice, A. Colombo, B. Meier, P. Serruys, C. Tamburino, G. Guagliumi, E. Sousa, H.-P. Stoll, and for the REALITY Trial Investigators
Sirolimus- vs Paclitaxel-Eluting Stents in De Novo Coronary Artery Lesions: The REALITY Trial: A Randomized Controlled Trial
JAMA,
February 22, 2006;
295(8):
895 - 904.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. N. Bairey Merz, L. J. Shaw, S. E. Reis, V. Bittner, S. F. Kelsey, M. Olson, B. D. Johnson, C. J. Pepine, S. Mankad, B. L. Sharaf, et al.
Insights From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: Gender Differences in Presentation, Diagnosis, and Outcome With Regard to Gender-Based Pathophysiology of Atherosclerosis and Macrovascular and Microvascular Coronary Disease
J. Am. Coll. Cardiol.,
February 7, 2006;
47(3_Suppl_S):
S21 - S29.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. W. Serruys, M. J.B. Kutryk, and A. T.L. Ong
Coronary-Artery Stents
N. Engl. J. Med.,
February 2, 2006;
354(5):
483 - 495.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Lee, H.-C. Tan, and Y.-T. Lim
Update on Drug-Eluting Stents for Prevention of Restenosis
Asian Cardiovasc Thorac Ann,
February 1, 2006;
14(1):
75 - 82.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Mehilli, A. Dibra, A. Kastrati, J. Pache, J. Dirschinger, A. Schomig, and for the Intracoronary Drug-Eluting Stenting to Abr
Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels
Eur. Heart J.,
February 1, 2006;
27(3):
260 - 266.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. C. Smith Jr, T. E. Feldman, J. W. Hirshfeld Jr, A. K. Jacobs, M. J. Kern, S. B. King III, D. A. Morrison, W. W. O'Neill, H. V. Schaff, P. L. Whitlow, et al.
ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)
J. Am. Coll. Cardiol.,
January 3, 2006;
47(1):
216 - 235.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. C. Smith Jr, T. E. Feldman, J. W. Hirshfeld Jr, A. K. Jacobs, M. J. Kern, S. B. King III, D. A. Morrison, W. W. O'Neill, H. V. Schaff, P. L. Whitlow, et al.
ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)
Circulation,
January 3, 2006;
113(1):
156 - 175.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Mauri, E. J. Orav, S. C. Candia, D. E. Cutlip, and R. E. Kuntz
Robustness of Late Lumen Loss in Discriminating Drug-Eluting Stents Across Variable Observational and Randomized Trials
Circulation,
November 1, 2005;
112(18):
2833 - 2839.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sabate, P. Jimenez-Quevedo, D. J. Angiolillo, J. A. Gomez-Hospital, F. Alfonso, R. Hernandez-Antolin, J. Goicolea, C. Banuelos, J. Escaned, R. Moreno, et al.
Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial
Circulation,
October 4, 2005;
112(14):
2175 - 2183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B. King III, G. Dangas, J. W. Moses, S. B. King III, G. Dangas, and J. W. Moses
Surgery Is Preferred for the Diabetic With Multivessel Disease
Circulation,
September 6, 2005;
112(10):
1500 - 1515.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Kataoka, S. Yasuda, I. Morii, Y. Otsuka, A. Kawamura, and S. Miyazaki
Quantitative Coronary Angiographic Studies of Patients With Angina Pectoris and Impaired Glucose Tolerance
Diabetes Care,
September 1, 2005;
28(9):
2217 - 2222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Windecker, A. Remondino, F. R. Eberli, P. Juni, L. Raber, P. Wenaweser, M. Togni, M. Billinger, D. Tuller, C. Seiler, et al.
Sirolimus-Eluting and Paclitaxel-Eluting Stents for Coronary Revascularization
N. Engl. J. Med.,
August 18, 2005;
353(7):
653 - 662.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Garot, T. Lefevre, M. Savage, Y. Louvard, W. R. Bamlet, J. T. Willerson, M.-C. Morice, and D. R. Holmes Jr
Nine-Month Outcome of Patients Treated by Percutaneous Coronary Interventions for Bifurcation Lesions in the Recent Era: A Report From the Prevention of Restenosis With Tranilast and its Outcomes (PRESTO) Trial
J. Am. Coll. Cardiol.,
August 16, 2005;
46(4):
606 - 612.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. V. Finn, F. D. Kolodgie, J. Harnek, L.J. Guerrero, E. Acampado, K. Tefera, K. Skorija, D. K. Weber, H. K. Gold, and R. Virmani
Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimus- or Paclitaxel-Eluting Stents
Circulation,
July 12, 2005;
112(2):
270 - 278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Mauri, E. J. Orav, and R. E. Kuntz
Late Loss in Lumen Diameter and Binary Restenosis for Drug-Eluting Stent Comparison
Circulation,
June 28, 2005;
111(25):
3435 - 3442.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A H Gershlick
Drug eluting stents in 2005
Heart,
June 1, 2005;
91(suppl_3):
iii24 - iii31.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Agostoni, G. G.L. Biondi-Zoccai, G. L. Gasparini, M. Anselmi, G. Morando, M. Turri, A. Abbate, E. P. McFadden, C. Vassanelli, P. Zardini, et al.
Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials
Eur. Heart J.,
May 1, 2005;
26(9):
881 - 889.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. W. O'Neill, S. R. Dixon, and C. L. Grines
The year in interventional cardiology
J. Am. Coll. Cardiol.,
April 5, 2005;
45(7):
1117 - 1134.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Valgimigli, C. A.G. van Mieghem, A. T.L. Ong, J. Aoki, G. A. R. Granillo, E. P. McFadden, A. P. Kappetein, P. J. de Feyter, P. C. Smits, E. Regar, et al.
Short- and Long-Term Clinical Outcome After Drug-Eluting Stent Implantation for the Percutaneous Treatment of Left Main Coronary Artery Disease: Insights From the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital Registries (RESEARCH and T-SEARCH)
Circulation,
March 22, 2005;
111(11):
1383 - 1389.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. T.L. Ong, A. Hoye, J. Aoki, C. A.G. van Mieghem, G. A. Rodriguez Granillo, K. Sonnenschein, E. Regar, E. P. McFadden, G. Sianos, W. J. van der Giessen, et al.
Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation
J. Am. Coll. Cardiol.,
March 15, 2005;
45(6):
947 - 953.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Moreno, C. Fernandez, R. Hernandez, F. Alfonso, D. J. Angiolillo, M. Sabate, J. Escaned, C. Banuelos, A. Fernandez-Ortiz, and C. Macaya
Drug-eluting stent thrombosis: Results from a pooled analysis including 10 randomized studies
J. Am. Coll. Cardiol.,
March 15, 2005;
45(6):
954 - 959.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Fajadet, M.-C. Morice, C. Bode, P. Barragan, P. W. Serruys, W. Wijns, C. R. Constantini, J.-L. Guermonprez, H. Eltchaninoff, D. Blanchard, et al.
Maintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Coronary Stents: Three-Year Results of the RAVEL Trial
Circulation,
March 1, 2005;
111(8):
1040 - 1044.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. M. Shrive, B. J. Manns, P. D. Galbraith, M. L. Knudtson, W. A. Ghali, and for The APPROACH Investigators
Economic evaluation of sirolimus-eluting stents
Can. Med. Assoc. J.,
February 1, 2005;
172(3):
345 - 351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schluter, J. Schofer, A. H. Gershlick, E. Schampaert, W. Wijns, G. Breithardt, and for the E- and C-SIRIUS Investigators
Direct stenting of native de novo coronary artery lesions with the sirolimus-eluting stent: A post hoc subanalysis of the pooled E- and C-SIRIUS trials
J. Am. Coll. Cardiol.,
January 4, 2005;
45(1):
10 - 13.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, D. Berman, G. K. Feld, B. H. Greenberg, J. D. Knoke, K. U. Knowlton, W. Y.W. Lew, J. Narula, D. Sahn, et al.
Highlights of the year in JACC 2004
J. Am. Coll. Cardiol.,
January 4, 2005;
45(1):
137 - 153.
[Full Text]
[PDF]
|
|
|
|
Top
Abstract
Patients and methods